The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
We’ve already got the contract! Just not how much will actually be utilised :)
Yes outlook is very bright, with a £374m contract about to be announced :)
Sensetslka, I like the market cap analogy you’ve used, as it being peanuts, as the Share has definitely attracted monkeys and rats, lol.
Just reposted this under new heading as someone requested
The LFT market is set to reach approximately 10Bn by 2025 and with the revenues generated from covid this will leave Omega very well positioned to take advantage of this growing market. It is more sensible to look forward at what Omega will become as opposed to backwards at what they were earning pre-covid.
They have HIV tests, growing demand for food intolerance tests (57% increase in revenue in 2020 and with a gross margin of 70% this adds significantly to the bottom line) and are looking to add both CrAG & TB lateral flow tests that we know of. I dare say there are a whole host of other lateral flow tests in the pipeline (Animal health, plant testing, environemtal testing etc..) which ODX will be looking to expand into.
All that said I still believe there will be demand for covid testing for years, we'll need 100% testing at the borders to prevent the import/export of any variants of concern and still need to heavily test the UK population to prevent the emergence of any immune system evading variants in the UK. From the coronavirus press conference last night the CMO presented a slide which shows a huge proportion of people who catch & transmit covid (but not die from it) are the last to get vaccinated. This is the same demographic that typically parties hard, goes to music festivals and mass gatherings a lot etc... If they are free to do what they like unabated then risk of a new variant emerging from within that group is significant hence why as the lockdown ends existing stockpiles of innova tests are going to diminish rapidly & huge demand for odx products will be realised. The virus will eventually become endemic of course which still will require a significant number of tests globally, in the long run, those with the most accurate tests will be generating revenue from covid indefinitely and then we have to consider future pandemics...
This is the birth of a UK diagnostics industry that is here to stay. 140m market cap is peanuts.